|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
ECONOMIC IMPACT OF THE INTRODUCTION OF SUBCUTANEOUS TRASTUZUMAB IN THE PHARMACOTHERAPEUTIC GUIDE
DE LA VEGA ZAMORANO IVÁN, APARICIO RUBIO CELIA, PRIETO CASTELLO MANUEL, SÁNCHEZ ALCARAZ AGUSTÍN, CUEVAS SANZ JOSÉ MIGUEL
Background: Trastuzumab (Herceptin®) has been recently marketed for subcutaneous administration in the treatment of breast cancer (precocious and metastatic) and metastatic gastric cancer. In May of 2015, this presentation was included in the Pharmacotherapeutic Guide after its approval in the Commission of Pharmacy
Purpose: Evaluate and quantify the economic impact of subcutaneous presentation.
Method: Analysis of the consumption of trastuzumab in patients who received at least one dose of subcutaneous trastuzumab between May 2015 and December 2016. The variables collected are number of patients, sex, age, weight, treatment cycles, diagnosis, stage and number of vials of drug used (intravenous and subcutaneous
Results: During the study period, a total of 453.6 intravenous trastuzumab and 197 subcutaneous vials were used, resulting in the expenditure of €558,289.72. The estimated cost without the introduction of subcutaneous administration vials in the same period would have been €588,536.72. The possibility of using the new presentation has resulted in a saving of €30,247.
Discussion: The inclusion of this presentation in the Pharmacotherapeutic Guide has been a great saving, which allows the rationalization of resources, universal access to new therapies, and ensure the sustainability of the National Health System.
ECONOMICAL ANALYSES – SUBCUTANEOUS – TRASTUZUMAB